{"name":"Servier","slug":"servier","ticker":"Private","exchange":"Private","domain":"servier.com","description":"Servier Laboratories is an international pharmaceutical company founded by Jacques Servier and now governed by a non-profit foundation, with its headquarters in France (Suresnes).","hq":"Suresnes, France","founded":0,"employees":"","ceo":"Olivier Laureau","sector":"Big Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":6000000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1980-01-01","label":"Detralex first approved","drug":"Detralex","drugSlug":"detralex","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Tibsovo first approved","drug":"Tibsovo","drugSlug":"ivosidenib","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Asparlas first approved","drug":"Asparlas","drugSlug":"calaspargase-pegol","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Voranigo first approved","drug":"Voranigo","drugSlug":"vorasidenib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-05-01","label":"Voranigo PHASE3 readout","drug":"Voranigo","drugSlug":"vorasidenib","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"Norvasc patent cliff ($1.5B at risk)","drug":"Norvasc","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Coversyl patent cliff ($500M at risk)","drug":"Coversyl","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Biosynthetic Human Insulin Injection","genericName":"Biosynthetic Human Insulin Injection","slug":"biosynthetic-human-insulin-injection","indication":"Other","status":"marketed"},{"name":"Detralex","genericName":"Detralex","slug":"detralex","indication":"Other","status":"marketed"},{"name":"Gliclazide MR and Insulin Glargine Injection","genericName":"Gliclazide MR and Insulin Glargine Injection","slug":"gliclazide-mr-and-insulin-glargine-injection","indication":"Other","status":"marketed"},{"name":"Voranigo","genericName":"VORASIDENIB","slug":"vorasidenib","indication":"Grade 2 astrocytoma","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Tibsovo","genericName":"IVOSIDENIB","slug":"ivosidenib","indication":"Acute myeloid leukemia, disease","status":"marketed"},{"name":"Asparlas","genericName":"CALASPARGASE PEGOL","slug":"calaspargase-pegol","indication":"Acute lymphoblastic leukemia","status":"marketed"},{"name":"Ivosidenib Oral Tablet","genericName":"Ivosidenib Oral Tablet","slug":"ivosidenib-oral-tablet","indication":"Acute myeloid leukemia (AML) with IDH1 mutation","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Diabeton 60 MR","genericName":"Diabeton 60 MR","slug":"diabeton-60-mr","indication":"Type 2 diabetes mellitus","status":"phase_2"}]}],"pipeline":[{"name":"Tibsovo","genericName":"IVOSIDENIB","slug":"ivosidenib","phase":"marketed","mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML.","indications":["Acute myeloid leukemia, disease","Biliary tract cancer"],"catalyst":""},{"name":"Asparlas","genericName":"CALASPARGASE PEGOL","slug":"calaspargase-pegol","phase":"marketed","mechanism":"Asparlas depletes asparagine, an amino acid that cancer cells rely on for growth.","indications":["Acute lymphoblastic leukemia"],"catalyst":""},{"name":"Biosynthetic Human Insulin Injection","genericName":"Biosynthetic Human Insulin Injection","slug":"biosynthetic-human-insulin-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Detralex","genericName":"Detralex","slug":"detralex","phase":"marketed","mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin.","indications":[],"catalyst":""},{"name":"Diabeton 60 MR","genericName":"Diabeton 60 MR","slug":"diabeton-60-mr","phase":"phase_2","mechanism":"Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Gliclazide MR and Insulin Glargine Injection","genericName":"Gliclazide MR and Insulin Glargine Injection","slug":"gliclazide-mr-and-insulin-glargine-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ivosidenib Oral Tablet","genericName":"Ivosidenib Oral Tablet","slug":"ivosidenib-oral-tablet","phase":"phase_3","mechanism":"Ivosidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that blocks the production of the oncometabolite 2-hydroxyglutarate, thereby promoting differentiation and apoptosis of IDH1-mutant cancer cells.","indications":["Acute myeloid leukemia (AML) with IDH1 mutation","Cholangiocarcinoma with IDH1 mutation","Other IDH1-mutant solid tumors (in development)"],"catalyst":""},{"name":"Voranigo","genericName":"VORASIDENIB","slug":"vorasidenib","phase":"marketed","mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1.","indications":["Grade 2 astrocytoma","Grade 2 oligodendroglioma"],"catalyst":""}],"recentEvents":[{"date":"2023-09-01","type":"regulatory","headline":"Servier Receives FDA Approval for Concor 5mg Tablet","summary":"Servier announced that the FDA has approved Concor 5mg tablet for the treatment of hypertension.","drugName":"Concor","sentiment":"positive"},{"date":"2022-06-15","type":"deal","headline":"Servier Partners with Pfizer to Develop New Cancer Therapies","summary":"Servier announced a partnership with Pfizer to develop new cancer therapies, including Trifluridin/Tipiracil.","drugName":"Trifluridin/Tipiracil","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOQlVJOG9adjQ3eGFvYVQxd01vcDFRQmpZekQyTDJrdEx6VFRHMGV0TTQtMWg1Y29nZ0dISUI4N09GRXc0dWhzaWpfR3hFa2k1dVVKSEE1bmZ6SFNkczZoa3NiSEhJYWR1ZzBqQVk3VjZTMnh2RUNxY2ZEenh0dDNxeGFuNA?oc=5","date":"2026-03-10","type":"pipeline","source":"Pharma Voice","summary":"Servier’s $2.5B cancer bet underlines a quick oncology growth strategy - Pharma Voice","headline":"Servier’s $2.5B cancer bet underlines a quick oncology growth strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFA4Q1dzc2NwdFVJU2JaenZEc2k4aDkzaVlHaDZQSDlFOEJjUk1MeHh1Z0VYWjdMREdqYVR2TGpkU2w0YkRadWJJNWh6TFV1aWF2TXVWeVNtR2pNQ3JUR0l6Z2VaYzNQdmJEZEtCVXMtVHFNM3RoT0dz?oc=5","date":"2026-03-06","type":"deal","source":"statnews.com","summary":"Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B - statnews.com","headline":"Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPV28tNFZLRFA1alY4TUNhQU10TlVwTWw1S2RfbVBpQVhMUU02QmRBT0ZnM2NvSTRJQmNXb0xxaDFWYzlhUEQyLUMwMGZSNUVlei1qSjN1dTFDWHdKUTJ0eFp6SUV2SU9WbkpGbWRUZXpfMGxuYkVpMHZaNDctMnp4NzE5RkxfTHc?oc=5","date":"2026-03-06","type":"pipeline","source":"pharmaphorum","summary":"Day One's big bet on tovorafenib just keeps paying off - pharmaphorum","headline":"Day One's big bet on tovorafenib just keeps paying off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPS3BIRmFqdUpacFczMVBPMjJROFU5U1NrclloY2NEVkxTRmROR2dSU2xENUVPelo0Vi1zcU5ZdTk2RkNtUGhfSDBEcnExeDg4RVFYbTRyZF9kMnRyZWNmM0J4UklFa2NvbXE3aGFyRmZyUkQzVGU1OFlRZzhYVnNXczJlXzRTcHJiWXhEQ0lpLTVyQm5aZ19UMjlMZDdrUmVZOUllVU15Rk0?oc=5","date":"2026-01-05","type":"deal","source":"The Pharma Letter","summary":"Insilico Medicine inks up to $888 million deal with Servier - The Pharma Letter","headline":"Insilico Medicine inks up to $888 million deal with Servier","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-11","type":"pipeline","source":"Express Pharma","summary":"Servier India launches biomarker testing initiative for AML and Cholangiocarcinoma patients - Express Pharma","headline":"Servier India launches biomarker testing initiative for AML and Cholangiocarcinoma patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPQzhOUmFQdjQ3YlNoWjE4Skl6aF9ia3hTNDB3bjhEQmlYSkFmX1JNT2FOX2RmREFZX3dKMzY5N0c4dTdhblpZakcwOG5VdXgzWG9zR2llNTVnb3I5bHlpUzRXaWlMRHpEUFVkemUxb0RtZ2gwdDhrY25RZW1XTDBlamxyQ0hzMmZPQ183UWNJUkFYNW9qdGNBVkVvejkzVDJmZUlmQ3ZuZHEwZG9mbm9sS0pORmVvNnVPVTZ4T2lvOGVuWmRWZGhsMDl0TWVsdEdBMkpEZDdvTHJrU09Lcm1pVkdrY1hheFVu0gHuAUFVX3lxTE5NdVhwMlR3TE1vTU1abzBaaExZbE9MMDcydzJyU0hHb0xrbmFiQ19jcmVyQ0pkb1lLVXNsVGNCMFB5RUNmNk1PNjdEaXVXQVdRWVI5aEVVelpRN1FQU1hVUWpCVEpVdHJ1djNGS3hka1hyMkpRNjVCRzV4eTFyS3QtaXVxNHR3Mm1WUmpvUVFuU3g5UVl3QVhsM3Vfb1VNNDFKRWlEOTdDX2dwbDBjY285akVNa2Z1QWJXU2JSSHVmXzRSeXFnSW1xaG9OamF2ZDB5VzQzS3E5WVoxeURuSnZZZFJySjNpTGM0Ynd0S2c?oc=5","date":"2025-11-11","type":"deal","source":"expresshealthcare.in","summary":"Servier India partners with Medgenome and Strand Lifesciences advance biomarker testing for IDH-mutated AML - expresshealthcare.in","headline":"Servier India partners with Medgenome and Strand Lifesciences advance biomarker testing for IDH-mutated AML","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNGhfWkJvWTZGaWc3dXFBNkFRUVFfSTcxR0lrZUJ2aEtLNHNHOFU5dk1kNzBhRk9yTVBQbDZMRGtabzJtR0N5WjI2ZTNrQmh2UTFsVlZhMHZsbnBTLUp5bzRabVhVUS15OTg1UmVDR2o4SEk5SkZjaXh2cTJzZmd3akc1cDJmOWEyX3VVQ3NqWVdzRTYxUDNQa253NnB2UWdVbXEtZ053d2hNRXRLS3l5b0pWMEhfbGdmbEdQTUozQ0wxSEd4bHdYbHZWeHNBcmEtckwzWVVkSmZTQ190OWRkUURydVFKOTl5ZFNBSDd3aUp1M2N3QkEtQ9IB_gFBVV95cUxPeHd1SFZQdW1aZlN3X3VWQU1kT0dGUFJiY0JBUW96Q1IzMEV6WGx3azEwZ29GTGNXZzVfb205aHJ3Rnd3M0hmU2RiS1hUTlBYQ243ZnhoNlM4NmdVX0lpaGIzZ01uM1BVVkNNaFliVXdYVEVUYVgyZmh2V3lyeHBvcGVHQlV0dFN4dFJGVmwwM19TSFpYR2czeGdYckJ5SVdjRm1lNXJ1bHR4Z3dWaFBTYVdwSDMxMXpkaHJoMVZyblBxMGlXYldDYVNqbi16dHZ1UGZ2blU3ZFhqRDVhbHJpcE5xWW5DS3BaWGtpR3BtUm5Jd3RPeDNodkZvbEdoZw?oc=5","date":"2025-11-11","type":"pipeline","source":"Business Today","summary":"Servier India rolls out affordable biomarker testing for leukaemia and bile duct cancer patients - Business Today","headline":"Servier India rolls out affordable biomarker testing for leukaemia and bile duct cancer patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNLXRldjVlb0xQMFZpVzFYSUNtdG56MWN0R3E3M3o0YlZIRmc0UkJTZHBXakFEcTdKLVlPeGVDYUNORGYwcjJxNW83d0pjUHhITmhCNnZfdFhMM3VTR0FHOUdEcl9rSmdwdFB0b2txdnI1bGVlYzMxOVVoc2dENVVtaGl0czM4QnFlVmU0Y1RrWGV4eGZfaTAtaWFvTjFna0R2UTgtcm9CU3FqZlNkS0ljQ254RnpiYkdmMW9ONWNFZGJpamhx?oc=5","date":"2025-07-31","type":"pipeline","source":"Dentons","summary":"Dentons advises Servier on the sale of Biogaran - Dentons","headline":"Dentons advises Servier on the sale of Biogaran","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNUDhUT0Jwa0Zxc0J3aGEtQWtOVG9LVVpuSHJLT0pCQWpQTVZ4RGItbUpJWkpGUW5VZzA0dXBIcHM5ZjFkVWNERE9LcmFnUVBOMHdSSkRHcGRIZ2JqSFVPcG1jRXlvLXpNM2RXNjlZb1Q1TWxtUVkybWtmWndZMDRTWVlTblRiYnBYZkZMNDliZmQwNHMyVXI1QWtza3pSZkxfZklxRFFnU0ZJUEV1ZHpn?oc=5","date":"2025-07-30","type":"deal","source":"Bloomberg.com","summary":"BC Partners to Acquire Servier’s Generic Drug Unit Biogaran - Bloomberg.com","headline":"BC Partners to Acquire Servier’s Generic Drug Unit Biogaran","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNMDNVSHYxXzZ2ZVRaSzBNeVJ4ZlE0UEhfVFhkOURhSUpwZy1ReWp6N3FLVmQ5MTBrVkVTME04TjBoTzE4Wnoza3ZwelI3QnhGcWxNcTJRTm1DbFc0YVd6QUxJaUl5NG9yelVEQm9ueDVQYmRPaF9qblhNb0ZCMTZjV0d4OGZ1WnpaWElRTGFFcWJTQk4zM3BULWRIcjBjTElLdnppTUloVTdidWtyQzF1SF9FQ2w?oc=5","date":"2025-07-30","type":"deal","source":"realdeals.eu.com","summary":"BC Partners to acquire Biogaran in French carve-out deal with a €800m to €1bn EV - realdeals.eu.com","headline":"BC Partners to acquire Biogaran in French carve-out deal with a €800m to €1bn EV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNazExUmxaeDlXSERnU3hPNXZDMW42b1VTNzc0cmxNSGxubkNZVG53N3Z1QjZmd19Bdl9TNy0tN0o1UTRMd2RYYUFpdHZ5aFE2NmluWmlsRnZtdmxLdksxRVA5Rkd0QUVydnpOTnBzRGZJcVpVLWtiMVI2a2xpYlptV3JOM2hYc1hvT0RIUk81UXRkNmplQ192YUFBSWlETE1vUWow?oc=5","date":"2025-03-21","type":"deal","source":"Servier","summary":"Open innovation: 3 Compelling Reasons to choose a Public-Private Partnership in Healthcare - Servier","headline":"Open innovation: 3 Compelling Reasons to choose a Public-Private Partnership in Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNNndxZ0JwSTJWMDlXZnptYXZYRGlNd3NQQVl5NjhSTWIxblBUbS1YNW5NZDZsMnAxYXpfMDg5LVpHTE1SeHhQNWxmQ1d3eDJwUUt1UzVfU1YyMV8zN1lBX2NsRFoxVHdCYVIydEhMYmhYNjNsLTN3dHpfT0lERmhuWkJTaFRwNkEtU0pDdC1wTEhNdlFJVnBHWmc3WFZfaUI2bGl1bF80OVFWVEhrQUtlQlc4dHBidUptZFNNZkZnQm1MUQ?oc=5","date":"2025-01-23","type":"pipeline","source":"Fierce Pharma","summary":"JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic' - Fierce Pharma","headline":"JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic'","sentiment":"neutral"}],"patents":[{"drugName":"Norvasc","drugSlug":"amlodipine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Coversyl","drugSlug":"perindopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":500000000}],"drugCount":8,"phaseCounts":{"marketed":6,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sanofi","Novartis","Merck & Co."],"therapeuticFocus":["Cardiovascular","Metabolic"],"financials":null,"yahoo":null}